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PENYARINGAN PERENCAT BERPOTENSI UNTUK PERENCATAN 
ISOCITRATE LYASE MYCOBACTERIUM TUBERCULOSIS:  
PENDEKATAN IN SILICO DAN IN VITRO 
 
ABSTRAK 
 
Tuberkulosis (juga dikenali sebagai penyakit batuk kering atau penyakit tibi) 
merupakan sejenis penyakit yang dijangkit oleh bakteria Mycobacterium tuberculosis 
(MTB). Wabak global ini telah menjangkiti satu per tiga populasi dunia tanpa mengira 
jenis jangkitan aktif atau laten. Dalam dua jenis jangkitan ini, MTB menjalani 
metabolism yang berbeza. Contohnya mereka mempunyai kitaran janaan tenaga yang 
berbeza semasa aktif dan laten. Bukannya menyasarkan sasaran ubat yang terlibat 
dalam metabolism semasa MTB aktif, penyelidikan ini menyasarkan isocitrate lyase 
(ICL), satu sasaran ubat yang terlibat dalam kitaran janaan tenaga semasa MTB dalam 
keadaan dorman (juga dikenali sebagain glyoxylate cycle). Kajian sebelum ini 
menunjukkan bahawa MTB yang dorman tidak dapat hidup dalam paru-paru model 
tikus tanpa ICL. Pada masa yang sama, ICL tidak wujud dalam mamalia. Jadi, ICL 
adalah sesuai digunakan sebagai sasaran ubat. Dalam kajian ini, simulasi dinamik 
molekul (MD, molecular simulation) dilakukan ke atas struktur kristal ICL terlebih 
dahulu dengan pakej AMBER 8. Hasil daripada 30 ns simulasi MD telah menunjukan 
bahawa lingkaran C-termina terlibat dalan jalan masuk ke tapak aktif. Melalui 
pengiraan MM-PBSA, didapati bahawa pengikatan substrat (isocitrate) adalah 
disumbangi oleh interaksi electrostatik dan hidrofobik. Kesatuan konformasi ICL yang 
dikumpul melalui simulasi MD telah digunakan untuk menyaring 3,000 kompoun 
kimia daripada tumbuhan tempatan Malaysia (NADI database). Penyaringan maya ini 
dilakukan dengan program AutoDock 3.05. Adalah didapati bahawa 22 calon 
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berpotensi telah memenuhi syarat Lipinski’s Rule of Five (kriteria ubat-rupa). Dalam 
22 calon berpotensi, 6 boleh didapati secara komersil sebagai kompoun tulen malah 
16 yang lain hanya boleh didapati melalui 12 tumbuhan (akhirnya hanya 10 tumbuhan 
sahaja yang didapati). Jadi 6 kompoun tulen dan 10 ekstrak tumbuhan telah digunakan 
dalan ujian aktiviti perencatan iaitu ujian enzim dan ujian disk difusi.  Ujian enzim 
dilakukan dengan mengguna MTB ICL yang diklon, diekspres dan ditulen malah ujian 
disk difusi mengguna model gantian MTB, iaitu M. smegmatis untuk menguji perencat 
ICL yang berpotensi cadangan penyaringan maya. Namun itaconate, perencet ICL 
yang diketahui dapat menunjuk aktiviti perenjatan, tetapi kompoun tulen dan ekstrak 
tumbuhan tidak. Dalam ujian disk difusi, empat ekstrak telah menunjukkan perenjatan 
aktiviti ICL iaitu ekstrak Manilkara zapota, Momordica charantia, Vitex negundo dan 
Morinda citrifolia, dengan kepekatan renjatan minima (MIC, minimum inhibitory 
concentration) masing-masing sebanyak 12.5 mg/ml, 12 mg/ml, 0.78 mg/ml dan 0.39 
mg/ml. Kepekatan baktericida minima M. zapota dan M. charantia adalah 25 mg/ml. 
Malah kepekatan baktericida minima V. negundo dan M. citrifolia adalah 1.6 mg/ml. 
Kombinasi eksperimen in silico dan in vitro ini telah berjaya mengenal pasti perencat 
MTB ICL yang berpotensi. Akan tetapi, pengoptimuman juga diperlukan untuk 
siasatan lanjut, contohnya pengajian aktiviti perencatan dengan ekstrak pecahan, 
pengenalan pasti kompoun yang terlibat dalan perencatan dan ujian lanjut atas 
kepekatan ekstrak yang berbeza dalam ujian enzim.  
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SCREENING FOR POTENTIAL INHIBITORS OF 
MYCOBACTERIUM TUBERCULOSIS ISOCITRATE LYASE:  
IN SILICO AND IN VITRO APPROACHES 
 
ABSTRACT 
 
Tuberculosis (TB) that is caused by Mycobacterium tuberculosis (MTB) still 
remains as global epidemic and affects one-third of the world population, regardless 
of active TB or latent TB infection. The metabolism for active and latent MTB are 
different, for instance they have different energy generation cycle during active and 
latent stage. Instead of focusing on the drug targets during the active stage, which 
already have the effective therapeutic drugs, this study targeted isocitrate lyase (ICL), 
a potential target for dormant (latent) MTB energy generation cycle (glyoxylate cycle). 
Studies showed that without ICL, dormant MTB cannot survives within the lung of a 
murine model. Besides, this enzyme is not found in mammals hence it is an appropriate 
drug target to eliminate TB. In this study, molecular dynamics (MD) simulations were 
first performed on the crystal structure of ICL, using AMBER 8 molecular dynamics 
package. Results from 30 ns of MD simulations showed that C-terminal loop is 
involved in the access towards the active site. In addition, MM-PBSA calculation 
showed that the substrate (isocitrate) binding was contributed by electrostatic 
interaction as well as the hydrophobic interactions. Ensemble conformations obtained 
from MD simulation were then used for virtual screening to search for the potential 
ICL inhibitor from Malaysian local plant database (NADI) with the collection of 3,000 
compounds. Virtual screening that performed with AutoDock 3.05 has managed to 
identify 22 potential candidates which are within Lipinski's Rule of Five (with drug-
likeliness criteria). Of the 22 candidates, 6 were commercially available as pure 
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compound while the remaining 16 candidates can only be obtained from 12 plants 
(however, only 10 plants were available during the study). Therefore, 6 pure 
compounds and 10 crude extracts were used to test for their inhibition activity by 
enzymatic assay and disc diffusion assay. In enzymatic inhibitory assay, MTB ICL 
was cloned, expressed and purified whereas disc diffusion assay used a replacing MTB 
model, M. smegmatis to test against the potential inhibitors suggested from virtual 
screening. The known inhibitors of ICL, itaconate managed to show inhibition in 
enzyme inhibitory assay but the pure compounds and crude extracts were not. 
Astonishingly, four crude extracts: Manilkara zapota, Momordica charantia, Vitex 
negundo and Morinda citrifolia showed inhibitory effect on M. smegmatis with 
minimal inhibitory concentration (MIC) of 12.5 mg/ml, 12 mg/ml, 0.78 mg/ml and 
0.39 mg/ml, respectively. M. zapota and M. charantia obtained minimal bactericidal 
concentration (MBC) of 25 mg/ml whereas V. negundo and M. citrifolia have MBC of 
1.6 mg/ml. The combination of both in silico and in vitro approaches managed to 
identify potential compounds for MTB ICL. However, optimization will be needed in 
future study e.g. inhibition study on the fractionated crude extract, identification of 
compounds that gave inhibition effects and further testing on different concentration 
of crude extract for enzymatic assay.   
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CHAPTER ONE 
GENERAL OVERVIEW 
 
1.1 Statement of the problem 
It is indisputable that Mycobacterium tuberculosis (MTB) is a resurgent 
infectious disease. Compounded to the problem are the multidrug resistant, extensively 
drug resistant strains and totally drug resistant strains. The development of current 
potential drugs, which mainly target on active phase MTB, is bound to face a certain 
extent of challenges when the drugs are no longer effective against the targets. The 
research on new drug target and new source of drug has thus become tougher and time 
consuming. This could be one of the reasons for no new treatment regime available 
since 40 years ago. In addition, no drug has been developed to target on latent phase 
MTB. If new drug can target on dormant phase MTB, TB dormancy might be able to 
be eradicated.  
 
1.2 General objective of the study 
The initial part of this study was to investigate the dynamics of MTB ICL and 
to screen against Malaysia Nature Product database (NADI) for MTB ICL potential 
inhibitors. The potential inhibitors from the screening was then is to test with in vitro 
experiment to evaluate their inhibitory potential by in vitro experiment. 
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1.3 Tuberculosis  
Tuberculosis (TB) is a lethal infectious disease caused by Mycobacterium spp., 
specifically Mycobacterium tuberculosis (MTB), first discovered in 1882 by Robert 
Koch (Youmans, 1979). MTB spread through air when an infected individual coughs, 
sneezes and talks. A sneeze with 3,000 nasal droplets would release 10,000 active 
MTB to the air. (Rinaggio, 2003). These MTB can float in the air by attaching to the 
dust and remain active in the air for several hours (Russell et al., 2010). Upon infection, 
these strict aerobic and acid-fast MTB can form tubercles at infected area and cause 
cellular necrosis, hence tuberculosis (Youmans, 1979).  
According to World Health Organization (WHO) Tuberculosis Facts (latest 
updated in year 2014), one-third of the world population has been infected with TB. A 
total of 95% TB mortality cases occurred in the developing countries. In Malaysia, 
Malaysian Health Fact from Ministry of Health Malaysia reported that TB has the 
highest mortality rate among the infectious diseases.  Despite the availability of drugs, 
TB therapy has been challenged by the long treatment regime which is last from 6 to 
24 months, multidrug resistant strains, HIV/AIDS and poverty. Under the premise of 
no new drug available in the past 40 years, this situation has spurred the urgent search 
for novel TB drug and its target. 
MTB survives in two phases, the replication phase (active TB) and the dormant 
phase (inactive TB). In these two different phases, MTB utilizes different metabolism 
pathway for different energy source. MTB consumes the carbohydrate and lipid as sole 
carbon source in replication and dormant phase, respectively. As these two phases 
undergo different metabolism pathways, possibility to share common enzyme is rather 
low. Under this circumstances, to select a common enzyme as the drug target which is 
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simultaneously important for both survival phase of MTB could be a pipe dream. 
Current available drugs are targeting at the enzyme involved in replication phase of 
MTB only, including one of the latest potential drug – TMC207. TMC207 which is 
currently in phase 2 efficacy study surprisingly showed bactericidal property against 
dormant MTB (Koul et al., 2008). However, no drug was available for those in 
dormant phase at the moment.  
 
1.3.1 Tuberculosis infection 
MTB can trigger primary infection (acute infection; MTB in replication phase) 
and also latent infection (persistent infection; MTB in dormant phase). Primary 
infection can be handled by cell-mediated immune response when MTB starts to 
replicate (Rinaggio, 2003). Although MTB are slow growing, they are still able to 
replicate before eliminated by slower cell-mediated immune response. When a patient 
is infected by MTB, MTB will usually attacks lung cavity to develop pulmonary TB 
as MTB will be phagocyted by alveolar macrophage when they enter via airways 
(Mohan, 2004; Russell et al., 2010). As shown in Figure 1.1, when MTB-phagocyted 
macrophage forms granuloma, the granuloma will undergo differentiation to become 
a more vascularised structure to mineralize and sterilize the infection (Russell et al., 
2010). Otherwise, the granuloma will undergo necrosis under certain circumstances 
such as HIV-infected or malnutrition, to release the infectious mycobacteria back to 
the airway (Russell et al., 2009).  
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Figure 1.1: Summary of Mycobacterium tuberculosis life cycle in human host. 
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Other than pulmonary TB, extra-pulmonary TB might also occur such as the 
central nervous system, the lymphatic system, the circulatory system, the genitourinary 
system, the gastrointestinal system, bones, joints, and even the skin (Mohan, 2004). 
Other species of Mycobacterium such as Mycobacterium bovis, Mycobacterium 
africanum, Mycobacterium canetti, and Mycobacterium microti can also cause TB but 
they are less common in human (Niobe-Eyangoh et al., 2003). TB patients usually get 
fatigue easily, losing weight, having fever and night sweat. In more serious cases, 
symptoms such as coughing, chest pain, coughing out blood-containing sputum, and 
difficulty in breathing will be observed (Arora, 2009). Further diagnose with chest x-
rays, analysis of sputum, and skin tests can be performed to confirm the disease. TB 
vaccine, Bacillus Calmette-Guérin (BCG) is available and there are also therapeutic 
TB drugs. To date, tuberculosis had killed more than 1.6 million mankind annually 
and persisted as latent infection in one-third of the world population (Ranjeet and 
Vinod, 2008; W.H.O, 2016). As MTB are able to cause persistent infection in immuno-
suppressed patients, HIV/AIDS population is one of the high risk populations. 
 
1.3.2 Drug resistance of Mycobacterium tuberculosis 
The therapeutic drugs are divided into first-line drugs and second-line drugs. 
The first-line drugs are isoniazid, rifampin, ethambitol and pyrazinamide whereas the 
second-line drugs include streptomycin, kanamycin, ethionamide, para-
aminosalicyclic acid, ofloxacin, capreomycin, amikacin and cycloserine  (Zumla et al., 
2013). However, the thick and waxy cell wall of MTB that is rich in novel lipids and 
polysaccharides formed a challenging barrier for the drugs to reach the respective 
target. Therefore, the treatment process is no doubt to be lengthy (Baker, 2007).  
During first six-months treatment using the combination of first-line drugs, MTB will 
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have sufficient time to establish drug resistance, even though they are extremely slow 
growing bacteria with doubling time of about 24 hours (Baker, 2007). If the patient 
could not be cured within the first 6 months, prolonged treatment up to two years with 
the second-line drug is needed to combat the drug resistant strain (Zumla et al., 2013). 
MTB mostly establishes drug resistance through chromosomal mutation 
(Johnson et al., 2006). When the attack of drugs cause the drug target’s gene mutation, 
the mutated strain (drug resistant strain) will keep replicating with the chromosome. 
Fortunately, the chromosomal locus that used to resist each drug is different (Johnson 
et al., 2006). Theoretically, the possibility for wild type MTB to obtain mutation more 
than two chromosomal loci simultaneously (multidrug resistant strain, MDR) is rather 
low. Yet, due to the low awareness, the MDR strains manage to be spread. The  MDR  
MTB strain is define as MTB which is resistant to at least both first line drug of 
isoniazid and rifampin (Johnson et al., 2006). Nowadays, not only MDR strain is 
getting more prevalence, extensively drug-resistant (XDR) strain that required third 
line drug (Zumla et al., 2013)  and totally drug-resistant (TDR) strain that resist to all 
first and second line drug is emerging fast (Velayati et al., 2009; Rowland, 2012; 
Udwadia et al., 2012). 
The current available drugs has low efficacy towards MTB in dormancy phase 
because they target only the drug targets involve replication phase (Getahun et al., 
2015). If there is any drug available for dormant MTB in the future, another challenge 
that can be foreseen is the drug delivery to dormant MTB-containing macrophage 
which is difficult to identify. As the drug during the dormant phase is still unavailable, 
the problem of drug resistance during the dormant phase is still unknown. 
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1.3.3 Mycobacterum tuberculosis in dormancy  
Replicating MTB located at the macrophage-rich centre of granuloma. When 
MTB is replicating, granuloma will actively recruits cell. Meanwhile, it is being 
surrounded by MTB-specific lymphocytes and enclosed by fibrous cuff. When 
granuloma increases in size, oxygen and nutrients could be hard to transport into the 
macrophage-rich centre (Russell et al., 2010). It is believed that when the macrophage-
rich centre of granuloma become hypoxic or nutrient deprivation, MTB will enter the 
dormant phase (Gengenbacher et al., 2010). However, it is not an easy task to study 
the in vivo macrophage environment. No work has successfully obtained an in vivo 
model of dormant MTB, only relied on several in vitro models. There are two well 
known in vitro models which study dormant MTB with different environment: the 
Wayne’s model (Wayne and Hayes, 1996) and Loebel’s model (Betts et al., 2002). 
Wayne’s model studied the dormant MTB behaviour in hypoxic yet nutrient rich 
medium but Loebel’s model used nutrient deprivation yet oxygen rich medium. 
Although both models have verified the viability of dormant MTB in respective 
survival environment, no data could actually confirm on which model can represent 
the real macrophage environment (Gengenbacher et al., 2010).  
Dormant phase MTB will be in non-replicating mode. In order to survive 
within the unfavourable environment in macrophage, MTB shifts its metabolism 
pathway. One of the obvious change is the carbon source during nutrients deprivation 
(Betts et al., 2002). Dormant MTB utilizes fatty acid or lipid as their sole carbon source 
instead of carbohydrate. The energy of MTB is produced via glyoxylate bypass instead 
of oxygen- dependent tricarboxylic acid cycle (TCA cycle; also known as Krebs cycle) 
(Singh and Ghosh, 2006). This interesting finding has lead the dormant MTB research 
to another milestone which is related to glyoxylate bypass. 
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1.3.4 Isocitrate lyase as drug target 
Krebs cycle is a common energy generating pathway if carbohydrate is the 
main carbon source. However, under nutrient depleted condition, global gene 
expression of MTB would shut down, including the gene expression for Krebs cycle 
(Betts et al., 2002). However, gene expression for glyoxylate pathway would not be 
affected (Gengenbacher et al., 2010). Glyoxylate pathway is a bypass of Krebs cycle 
or sometimes called the modified Krebs cycle (Dunn et al., 2009). Without ordinary 
substrate of carbohydrate, nutrient-starved dormant MTB utilizes lipid as the sole 
carbon source to generate energy.  
Figure 1.2 shows the comparison of Krebs cycle and glyoxylate bypass. The 
early phase of glyoxylate pathway is similar to Krebs cycle. Acetyl-CoA is the only 
substrate for both glyoxylate and Krebs cycle but the source of acetyl-CoA is different. 
Carbohydrate has to undergo glycolysis to generate acetyl-CoA for Krebs cycle. 
Meanwhile, lipid has to undergo beta-oxidation to obtain acetyl-CoA for glyoxylate 
cycle. The point of divert for these two pathways begin when acetyl-CoA converts into 
isocitrate. For the glyoxylate pathway, two important enzymes are needed namely 
isocitrate lyase (ICL) and malate synthase (MS). Isocitrate lyase is responsible to 
cleave the isocitrate into glyoxylate and succinate whereas malate synthase converts 
glyoxylate into malate by adding an acetyl group.  
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Figure 1.2: The Krebs cycle and the glyoxylate pathway for energy generation. The 
blue bold arrow indicates the Krebs cycle and the red arrow shows the glyoxylate 
bypass. 
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Both ICL and MS were potential drug targets. The drug ability of MS has been 
proved and various studies have been carried out to optimize its usage (Smith et al., 
2003; Kinhikar et al., 2006; Arora, 2009; Krieger et al., 2012). On the other hand, 
several high throughput screening has been carried out to search for ICL inhibitor at 
the same time. It was found that its drug availability is not as good as MS. One 
explanation found regarding the cavity size of the active site. ICL active site is 
relatively small in capacity compared with that of MS (Krieger et al., 2012; Sharma et 
al., 2000). Other than this, not much research has been published to further explain 
about the low drug availability of ICL. This has incited the interest in this study to 
understand ICL. 
 
1.3.5 Isocitrate lyase related studies 
The structure of MTB ICL in Figure 1.3 was solved in year 2000 by Sharma et 
al. They reported that ICL is stable as dimers but functional in tetramer. Each of the 
subunits has an unusual α/β barrel as the largest core domain which is formed by of 
eight α-helix and β-strand respectively. Each subunit has an extra helix that projected 
out from the barrel and another two ensuing helix involved in the interaction among 
the subunits. On top of the barrel, there is an important small β-domain which has 
several active side residues.  
There are a total of three ICL structures solved by Sharma et al.(2000). The 
first structure is a ligand-free ICL which is in “open conformation” (PDB id: 1F61). 
When ligand glyoxylate and succinate (PDB id: 1F8I); or pyruvate (PDB id: 1F8M) 
binds, they trigger a conformational change to make the ICL shift into a “close 
conformation”. ICL is an enzyme that is able to perform reversible catalysis of  
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Figure 1.3: The structure of ICL from MTB. a) Tetramer, each colour represents a 
subunit of ICL; b) dimer, cyan and orange represents monomer 1 and monomer 2; c) 
dimer in open conformation; d) ICL dimer in close conformation; e) monomer 1 in 
open conformation without ligand; and e) monomer 1 in close conformation with 
ligand. Purple represents the active site (Sharma et al., 2000; Lee et al., 2015).  
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isocitrate, meaning that it is able to cleave as well as form isocitrate. However, no 
study has been published on the interaction between the ICL and isocitrate. The 
catalytic mechanism of forming isocitrate form glyoxylate and succinate was only 
partly described (Sharma et al., 2000). The cleavage mechanism of isocitrate to 
produce glyoxylate and succinate is remain unknown. 
According to Dunn et al. (2009), ICL gene is not found in any placental 
mammals. Muñoz-Elías and McKinney (2005), showed that there are 2 types of ICL 
exist in MTB: the ICL 1 (prokaryotic-like isoform) and ICL 2 (eukaryotic-like 
isoform). ICL1 and ICL2 are jointly required for MTB. Absence of either one of them 
causes little effect for MTB but absence of both will cause MTB being eliminated from 
the lungs. Gould et al.(2006) reported that ICL 1 has dual roles. ICL 1 is needed in 
both glyoxylate cycle and methylcitrate cycle in MTB. Methylcitrate cycle is a cycle 
that removes the by-product of lipid beta-oxidation, the propionyl-CoA, which is toxic 
to MTB.  In this cycle, 3 enzymes needed are methylcitrate synthase, methylcitrate 
dehydrogenase and 2-methylisocitrate lyase (MCL). It was found that MTB only 
produces methylcitrate synthase and methylcitrate dehydrogenase but not MCL. The 
function of MCL was carried out by ICL 1. This study has thus shown that ICL is more 
important than expected (Gould et al., 2006). 
 Another research topic highlighted is the screening of inhibitor of ICL. 
According to the review by Dunn et al.(2009), the well-known ICL inhibitors include 
itaconate, 3-nitropropionate, 3-bromopyruvate, malate and oxalate (Bentrup et al., 
1999; McFadden and Purohit, 1977). Most of the inhibitors were analog of the natural 
substrate. However, they were later proven toxic and non-specific to develop into drug 
as they will inhibit some of the important metabolism enzymes which are 
simultaneously exist in both human and MTB. For instance, one of the succinate 
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analogs, 3-nitropropionate cause neurotoxicity (Greene et al., 1998). Another 
succinate analog, itaconate affect the growth of rat (Booth et al., 1952) and also cause 
hypertonicity for cat’s blood pressure (Finkelstein et al., 1947). Whereas, the analog 
of glyoxylate, 3-bromopyruvate is an energy blocker (Ko et al., 2004; Shoshan, 2012). 
 There are a few high throughput screening of ICL were reported. Two groups 
have reported their works in year 2006. First project is carried out by Global Alliance 
for TB Drug Development and GlaxoSmithKline, extensively screen for ICL inhibitor 
via high throughput screening. However, the project was terminated as the outcome 
was modestly successful (Global Alliance For TB Drug Development, 2010) In the 
same year, a Chinese group searched for potential ICL inhibitors from traditional 
Chinese medicine. They concluded that extracts form Illicium verum and Zingiber 
officinale were able to inhibit ICL (Bai et al., 2006). Unfortunately, the lead compound 
for ICL inhibition is remains unknown. In later years, the searching efforts continued 
by some groups with their respective in house chemical compound library. Their HTS 
managed to identify lead compound I2906 (Lu et al., 2010), Ydcm67 (Ji et al., 2011) 
and IMBI-3 (Liu et al., 2016) as the potential inhibitor for ICL. More ICL potential 
inhibitors that was screened with various strategies such as using MTB ICL and non-
MTB ICL as well as screening from natural compound or synthetic compound were 
summarized in a Table 1.1 (Lee et al., 2015). 
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Table 1.1: Summary of synthetic and natural potential inhibitor for MTB ICL and non-MTB ICL. 
No. 
Published 
Year 
Inhibitor Source Description Target ICL 
Inhibition* 
(IC50) 
Remarks 
1 1977 
Itaconate (McFadden and Purohit, 
1977; Bentrup et al., 1999) 
OH
O
CH2O
OH
 
 
Synthetic  
Succinate 
analog 
Pseudomonas 
indigofera 
Ki = 120 Established inhibitor 
2 1982 
3-nitropropionate (Schloss and Cleland, 
1982; Bentrup et al., 1999) 
N
+
O
-
O
O
O
-
 
 
Synthetic 
Succinate 
analog 
Pseudomonas 
indigofera 
Ki = 120 Established inhibitor 
3 1990 
Mycenon (Hautzel et al.) 
H Cl
CH3
Cl
Cl
OH
O
O
 
Mycena sp. Fungi 
Acinetobacter 
calcoaceticus 
Neurospora crassa 
Ricinus communis 
 
5.2 μM 
7.4 μM 
No information on 
positive control 
15 
 
4 1990 
3-bromopyruvate (Ko and McFadden, 
1990; Bentrup et al., 1999) 
O
O
OHBr
 
 
Synthetic 
Glyoxylate 
analog 
Escherichia coli 3 μM Established inhibitor 
5 2005 DNAzyme (Li et al., 2005) Synthetic - 
Mycobacterium 
tuberculosis 
-  
6 2006 
Extract of Traditional Chinese 
Medicine (Bai et al.) 
Zingiber officinale,    
Illicium verum 
Plant 
Mycobacterium 
tuberculosis 
47.7 μg/ml            
18.2 μg/ml 
Positive control      
IC50 of itaconate                
= 90 μg/ml 
(Good inhibitory) 
7 2007 
Hydroquinone derivatives (Yang et al.) 
OH
OH
R
R
1
 
 
Synthetic - Candida albicans 0.28-1.02 mM 
Positive control     
IC50 of itaconate                
= 0.06  mM 
(Weak inhibitory) 
 
 
 
       
16 
 
8 2007 
Halisulfate 1 (Shin et al., 2007; Lee et 
al., 2007b) 
OSO3Na
H OH
CH3
CH3
HCH3
CH3
CH3
OH
 
 
Hippospongia sp. 
Marine 
sponge 
Magnaporthe grisea 12.6 μM 
No information on 
positive control 
(High inhibitory) 
9 2007 
Bromophenols (Lee et al.) 
OH
OHOH
OH
Br
Br
Br
Br
 
Br OH
OHOH
OH
Br
Br
OR
 
 
Odonthalia 
corymbifera 
Red algae Magnaporthe grisea 2.0 – 2.8 μM 
Positive control      
IC50 of                      
3-nitropropionate               
= 94.2 μM 
(High inhibitory) 
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10 2008 
Polyoxygenated diterpenes (Jang et al.) 
H
CH3COO
OH
OCOCH2CH2CH3
H
R
1
R
2
R
3
 
H
OH
CH3COO
OCOCH2CH2CH3
H
R
1
R
2
R
3
 
H
OH
R
2
H
OCOCH 2CH2CH3
OCOCH 2CH2CH3
OCOCH 2CH2CH3
R
1
 
 
Phorbas sp. 
Marine 
sponge 
- 
LC50 of                       
55  - 140 μg/ml 
No information on 
positive control 
(Weak inhibitory) 
11 2008 
Meroditerpenoids (Jung et al.) 
H3CO
O
OH
O
R
 
OH
OH
R
H3CO
O
 
Sargassum 
siliquastrum 
Brown algae Candida albicans 50 – 95 μg/ml 
No information on 
positive control  
(Weak inhibitory) 
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12 2008 
Dihydroxystyrene metabolites (Chang 
et al.) 
OH
OH R
 
 
Association of 
Poecillastra 
wondoensis and 
Jaspis sp. 
Marine 
sponge 
Candida albicans 
28.7 to >200 
μg/ml 
Positive control     
IC50 of itaconate                
= 5.8 μg/ml 
(Weak to moderate 
inhibitory) 
13 2008 
Sesterterpenoids (Wang et al.) 
OH
O O
OH
O O
 
O
O
O
CO2H
 
 
Sarcotragus sp. 
Marine 
sponge 
Candida albicans 
12.5 – 19.9 
μg/ml 
Positive control     
IC50 of Itaconate                
= 4.9 μg/ml 
(Moderate to high 
inhibitory) 
 
 
 
 
 
       
19 
 
14 2008 
Sesterterpene sulphates (Lee et al.) 
N
CH3
CH3
NH
-
NH
-
H
O
O
S
O
O
O
-
 
O
O
S
O
O
O
-
N
CH3
CH3
NH
-
NH
-
 
 
Dysidea sp 
Marine 
sponge 
Candida albicans 31.3 – 33.8 μM 
Positive control IC50 
of 3-nitropropionate      
= 50.7 μM 
(High inhibitory) 
15 2009 
Pthalazinyl derivatives (Sriram et al., 
2009) 
R
R
1
F
Br
O
O
N
N
N
NH
 
 
Synthetic - 
Mycobacterium 
tuberculosis 
45 – 61%       
inhibition at 10 
μM 
Positive control        
3-nitropropionate has 
63.2% inhibition at 
100 μM 
        
20 
 
16 2009 
Hyrtiosin B (Lee et al.) 
OH
OO
OH
N
H
N
H  
 
Hyrtios sp. 
Marine 
sponge 
Candida albicans 89 μM 
Positive control     
IC50 of                      
3-nitropropionate          
= 50.7 μM 
(High inhibitory) 
17 2010 
Phthalazin-4-ylacetamide (Sriram et al., 
2010b) 
N
N
NH
R
O
O
Br
F  
N
N
O
O
Br
N
N
R
 
 
Synthetic - 
Mycobacterium 
tuberculosis 
40.62 – 66%     
inhibition at 10 
μM 
Positive control        
3-nitropropionate has                 
68.2% inhibition at 
100 μM 
        
21 
 
18 2010 
Extract of Traditional Chinese 
Medicine (I2906 ) (Lu et al., 2010) 
O
NH
OH
N
CH3 O
NH
O
CH3 
 
- Plant 
Mycobacterium 
tuberculosis 
134 μg/ml 
Control samples were 
untreated samples 
19 2010 
5-Nitro-2-furoic acid hydrazones with 
furan-2-carbaldehyde (Sriram et al., 
2010c) 
OO2N
NH
O
N
O
NO2
 
 
Synthetic  - 
Mycobacterium 
tuberculosis 
86.8%             
inhibition at 
10 mM 
Positive control        
3-nitropropionate has                 
63.2% inhibition at 
100 μM 
(Good inhibitory) 
20 2010 
Bromophenols (Oh et al.) 
OH
OHOH
OH
Br
Br
Br
Br O
 
 
Synthetic  - Candida albicans 2.65 μM 
Positive control     
IC50 of                      
3-nitropropionate      
= 50.7 μM 
(High inhibitory) 
22 
 
21 2010 
5-Nitro-2,6-dioxohexahydro-4-
pyrimidinecarboxamides (Sriram et al., 
2010a) 
NHNH
O
NO2
N
O
O
N N
O
OH
F
O
F
 
 
Synthetic  - 
Mycobacterium 
tuberculosis 
45.7%       
inhibition at 
10 mM 
Positive control        
3-nitropropionate has 
68.2% inhibition at 
100 μM 
(Good inhibitory) 
22 2010 
Indole-containing natural compound 
(analog) (Lee et al.) 
N
H
NH
OMe
 
 
Synthetic  - Candida albicans 75 μM 
Positive control     
IC50 of                      
3-nitropropionate         
= 50 μM 
(High inhibitory) 
23 2010 
Isatinyl thiosemicarbazones derivatives 
(Banerjee et al., 2011) 
N
N
NH
NH
O
S
O
N
N
N
F
O
O
OH
 
 
Synthetic  - 
Mycobacterium 
tuberculosis 
63.44%            
inhibition at 
10 mM 
Positive control        
3-nitropropionate has                 
65.9% inhibition at 
100 mM 
(Good inhibitory) 
23 
 
24 2011 
Brominated resorcinol dimer 
(Bouthenet et al.)  
OH
OH
OH
OH
Br Br
 
 
Synthetic - Candida albicans 28 μM 
Positive control      
IC50 of                       
3-nitropropionate      
= 6.0 μM 
(Good inhibitory) 
 
25 2011 
Sargachromanols (Chung et al.) 
O
R
OH  
 
Sargassum 
siliquastrum 
Brown algae Candida albicans 
118.4 – 172.9 
μM 
Positive control      
IC50 of                      
3-nitropropionate      
= 34.8 μM 
(Moderate inhibitory) 
26 2011 
Scalarane Sesterterpenes (Jeon et al.) 
OOAc
O
H
H3CO
H
H
 
OH
OOAc
H
OH
H
H
 
Hyatella sp. 
Marine 
sponge 
Candida albicans 40.8 – 55.3 μM 
Positive control IC50 
of 3-nitropropionate      
= 27.9 μM 
(Weak inhibitory) 
24 
 
27 2011 
Suvanine salt (Bae et al.)  
OSO3R
O
H
H
H
 
 
Coscinoderma sp. 
Marine 
sponge 
Candida albicans 5 – 17 μM 
Positive control IC50 
of  3-nitropropionate      
= 27.9 μM 
(Moderate inhibitory) 
28 2011 Chelerythrine extract (Liang et al.) Chelidonium majus Plant 
Mycobacterium 
tuberculosis 
Expression level 
decreased 5 fold 
- 
29 2011 
 
Mannich base, Ydcm67 (Ji et al.) 
NH
O
Cl
COOH
O  
 
Synthetic - 
Mycobacterium 
tuberculosis 
57.4% inhibition 
at 0.05mg/ml 
Positive control  
oxalic acid has 
95.55% inhibition at 
0.05M 
30 2011 Peptide inhibitor (Yin et al.) Synthetic - 
Mycobacterium 
tuberculosis 
Inhibition rate         
38.2 – 47.92%  
Samples contain no 
peptide inhibitor or 
ICL in reaction 
system as controls 
 
 
       
25 
 
31 2011 
3-nitropropionamides derivatives 
(Sriram et al.) 
O
-
N
+
O
O
N
N
OCH3
F COOH
O  
 
Synthetic - 
Mycobacterium 
tuberculosis 
0.1 μM 
Positive control           
IC50 of                            
3-nitropropionate      
= 116.0 μM 
(Good inhibitory) 
32 2012 
Pyruvate-isoniazid analog with their 
copper complex (Shingnapurkar et al.) 
OH
O
N NH
R
O
 
HOH3C
H20
Cu
O
O
N N
H
R
O
 
 
Synthetic - 
Mycobacterium 
tuberculosis 
Inhibition rate              
6 – 92 % 
Control docking 
using pyruvic acid 
33 2012 
Bahamaolides A (Macrolide) (Kim et 
al.) 
O
O OH
OH
OHOHOHOHOHOHOH  
Streptomyces sp. 
Actinomycet
e 
(Actinobacte
ria) 
Candida albicans 10.8 μM 
Positive control           
IC50 of                           
3-nitropropionate      
= 20.1 μM 
 (High inhibitory) 
